Pharmaceuticals News and Research

RSS

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

UCLA scientists have identified two chemicals that convince cells to ignore premature signals to stop producing important proteins. Published in the Sept. 28 edition of the Journal of Experimental Medicine, the findings could lead to new medications for genetic diseases, such as cancer and muscular dystrophy, that are sparked by missing proteins.

29 Sep 2009

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.

29 Sep 2009

Additional countries to join in donating H1N1 vaccines to developing countries, U.N official says

Additional countries are expected to soon announce they will follow in the footsteps of nine developed countries who recently said they would donate H1N1 (swine flu) vaccine supplies to poorer nations, David Nabarro, of the U.N. said Friday, Reuters reports.

29 Sep 2009

SOHM launches 26 branded generic pharmaceutical products in India

SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today the launch of 26 branded generic pharmaceutical products in India. The Company has already appointed two distributors in Northern India covering the largest state of India with a population of almost 1.5 billion people.

28 Sep 2009

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

MarkMonitor®, the global leader in enterprise brand protection, today released the company’s latest Brandjacking Index®, which finds a parallel online system of pharmaceutical supply and demand fueled by continued growth in listings for pharmaceuticals on business-to-business (B2B) exchange sites as well as increased traffic to illicit pharmacies. The report also reveals a growth in pharmaceutical brandjacking for popular drug brands.

28 Sep 2009

Laureate Pharma sign development and manufacturing agreement with ZZ Biotech

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a development and manufacturing agreement with ZZ Biotech, LLC. According to the agreement, Laureate will produce Activated Protein C variant under cGMP conditions. Terms of the manufacturing agreement were not disclosed.

28 Sep 2009

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

Quintiles opens an expanded regional facility

To enhance service offerings throughout Europe, Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. The purpose-built facility consolidates three buildings into a single state-of-the-art complex.

28 Sep 2009

Network in Canada to develop biomaterials for treatment of eye diseases

Researchers in Canada have established a new university/industry network to pursue the development of biomaterials, medical devices and drug delivery systems to treat the increasing incidence of eye disease.

26 Sep 2009

Contagious diseases more prevalent due to presenteeism

While employers may celebrate a low absenteeism rate among their employees, there may be a more serious problem if sick employees are coming to work. "Presenteeism," a new term coined for when employees work while unhealthy, may be even worse for employers and for the healthcare system, costing $160 billion annually in lost productivity, according to healthcare market research firm Kalorama Information, in its new report "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets." The report also notes that presenteeism costs are one of many factors driving usage of wellness programs.

26 Sep 2009

Cantwell amendment will raise cost of prescription drugs: PCMA

“America’s pharmacy benefit managers (PBMs) believe strongly in the principle of transparency and empowering payers to make informed health-care purchasing decisions resulting in lower prescription drug costs and higher quality. Regrettably, today’s amendment moves the health care system in the opposite direction.”

26 Sep 2009

Teva to market generic version of AstraZeneca's antipsychotic agent Seroquel tablets

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable conduct related to U.S. Patent No. 4,879,288.

26 Sep 2009

Auxilium Pharmaceuticals declares pricing of common stock shares

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced the pricing of a public offering of 3 million shares of its common stock.

26 Sep 2009

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

International drug makers are expected to produce three billion doses of the H1N1 (swine flu) vaccine, "enough for just under half the world's population," a WHO official said Thursday, Canwest News Service/Ottawa Citizen reports. "The agency was hoping pharmaceutical companies would be able to make about five billion doses a year, but data collected over the summer led to the revised estimate," the news service writes (Fitzpatrick, 9/24).

25 Sep 2009

At Finance Committee, fireworks surround efforts to add drug discount, eliminate individual mandate

The Senate Finance Committee on Thursday defeated an amendment that sought to squeeze more money out of pharmaceutical companies to help pay for the costs of changing the health care system. The panel's vote was a victory for President Obama and Finance Chairman Max Baucus.

25 Sep 2009

Recipients of the Lundbeck Neonatal Nursing Career Path Scholarship announced

The National Association of Neonatal Nurses (NANN) is proud to announce the recipients of the Lundbeck Neonatal Nursing Career Path Scholarship. The program, made possible through a grant from Lundbeck Inc. (formerly Ovation Pharmaceuticals), supports clinical neonatal nurses who seek to advance their education and become neonatal nurse practitioners.

25 Sep 2009

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct ownership of technology for which it had previously exercised its option to exclusively license from Advirna LLC.

25 Sep 2009

DOR Biopharma to raise $3.85 million from institutional investors

DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

25 Sep 2009

Pharmaceuticals News and Research

Ligand and GSK amend agreement to pursue independent research programs

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

Additional countries to join in donating H1N1 vaccines to developing countries, U.N official says

SOHM launches 26 branded generic pharmaceutical products in India

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

Laureate Pharma sign development and manufacturing agreement with ZZ Biotech

Phase 2 clinical trial results of IMO-2055 announced

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles opens an expanded regional facility

Network in Canada to develop biomaterials for treatment of eye diseases

Contagious diseases more prevalent due to presenteeism

Cantwell amendment will raise cost of prescription drugs: PCMA

Teva to market generic version of AstraZeneca's antipsychotic agent Seroquel tablets

Auxilium Pharmaceuticals declares pricing of common stock shares

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

At Finance Committee, fireworks surround efforts to add drug discount, eliminate individual mandate

Recipients of the Lundbeck Neonatal Nursing Career Path Scholarship announced

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

DOR Biopharma to raise $3.85 million from institutional investors

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring